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ABSTRACT 
Experimental investigations have shown that drug abuse initiates a cascade of 
pathophysiological events including toxic and hypoxic-ischemic injury on neurons, 
microglia and astrocytes, which finally lead to widespread disturbances in the brain. 
There are many reports about the psychiatric and neurologic effects of multiple drug 
abuse, but only a few clinical studies reporting possible correlation between 
recreational illicit drugs and gliomas.  
In this paper we present the case of a 40 years-old male patient, with a long 
history (almost ten years) of multiple drug abuse, including cocaine, heroin, 
marijuana, ethnobotanical drugs and nicotine, who was diagnosed and surgically 
treated for a supratentorial secondary giant cell glioblastoma (sgcGB) developed in a 
diffuse astrocytoma NOS. Depending on the type of the illicit drug used by the patient 
and the moment of life he used them, the morphological features identified in the 
histological samples of our patient confirmed the gliomagenesis effect of chronic 
multiple drug abuse, but also its inhibitory effects on tumour cells growth. This was 
due to the fact that although the tumour was large in size and caused brain sub-
falcine herniation, the patient reported the onset of seizures only late in the evolution.  
In conclusion, the diagnosis of a brain tumour should take into consideration not 
only patient's clinical and imaging data, but also his lifestyle, especially his addiction 
to recreational drugs. 
 
INTRODUCTION 
The Psychostimulants (cocaine, methamphetamine, etc.), opiates and 
opioids (heroin, methadone, etc.), sedatives (benzodiazepines), and  
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some other drugs such as cannabis (marijuana) and 
nicotine are the most widely consumed recreational 
drugs in order to obtain a sense of well-being. 
Unfortunately, in the same time, these drugs of 
abuse have a significant negative impact on public 
health as they can induce pulmonary (1-4), 
cardiovascular (5, 6), renal diseases (7), 
gastrointestinal and endocrine diseases or infections 
(8). 
However, psychiatric and neurologic symptoms 
are the most common manifestations of drug abuse 
toxicity. Along with the psychotic effects of 
recreational psychostimulants (9, 10), there are also 
reports of their neurological side effects, such as 
vasogenic edema formation (11), cerebral and spinal 
cord infarction, cerebral vasculitis associated with 
intraparenchymal or subarachnoid haemorrhage 
(12), hypoxic-ischemic leukoencephalopathy (13), 
ischemic optic neuropathy as well as partial and 
generalized seizures (14, 15).  
Some researchers have made systematic 
histological, immunohistochemical and 
morphometric investigations in order to identify the 
morphological alterations in the brains of multiple 
abusers. There are reports of intramyelinic edema 
and mitochondrial dysfunction due to cocaine abuse, 
but also of neurovascular toxicity due to heroin (16). 
Other studies reported a toxic spongiform 
leukoencephalopathy after intravenous heroin 
injection or after inhaling heroin vapors (17-19). The 
morphological substrate of this disease is a 
spongiform demyelination that develops due to a 
dysfunction of the oligodendrocyte mitochondria 
(20, 21). 
Neuropathological features encountered 
included neuronal loss, neurodegenerative 
alterations with significant widespread axonal 
damage (22), specific astroglial reaction patterns (23, 
24), with a reduction of glial fibrillary acidic protein-
immunopositive astrocytes, concomitant microglial 
activation as well as reactive and degenerative 
changes of the cerebral microvasculature (due to 
alterations of the endothelial cell and the basal 
lamina) (25). Fredericks et al. reported 
nonnecrotizing, nonleukocytoclastic small-vessel 
arteritis associated with cocaine use (26). On the 
molecular level, alterations in the expression of 
transcription factors and changes of brain 
neurotransmitter systems have been reported, too 
(27).  
All these results have provided evidence that 
drugs of abuse initiate a cascade of 
pathophysiological events including toxic, hypoxic-
ischemic injury, microglial and astrocytic - associated 
cytokine releases, which finally lead to widespread 
disturbances within the complex network 
of central nervous system cell-to-cell interactions 
(25, 28).  
However, as far as we know, there is a scarcity of 
literature concerning the correlation of drug abuse 
with the development of a cerebral glioma. There is 
only one epidemiological study published in 2004 by 
Efird et al. that found a 2.8-fold increased risk for 
malignant primary adult-onset glioma for people 
who had smoked cannabis once or more per month 
(29).  
In this paper we present the case of a 40 years 
male patient, a chronic multiple abuser for ten years, 
who was diagnosed and treated for a supratentorial 
secondary giant cell glioblastoma (sgcGB) developed 
in a diffuse astrocytoma NOS. We discuss the 
possible role of drug of abuse effects on tumour 
initiation, development and progression taken into 
consideration patient's history of multiple abuse.  
 
CASE PRESENTATION 
A male patient, 40 years old, heavy smoker (about 20 
cigarettes per day for 30 years), was brought by his 
family to the “Socola” Institute of Psychiatry, Iași, 
Romania, for strong headache and altered mental 
status over the last 24 hours. They considered that 
patient's status was the effect of his dependence on 
psychoactive substances as he had a long history 
(almost ten years) of multiple abuse, including 
cocaine, heroin, marijuana, and ethnobotanical 
drugs. Firstly, he used cocaine for five years, then he 
continued with heroin and marijuana for another 
two years and finally he only consumed 
ethnobotanical drugs over the most recent three 
years. The patient's relatives also declared that he 
had symptoms of anger or euphoria and changes in 
behaviour over the last twelve months, but also a 
state of sleepiness in the last month.  
The patient complained of intermittent diffuse 
headaches, which developed during the preceding 
months and improved with the use of 
ethnobotanical drugs.  
On physical examination the patient was 
apparently conscious, cooperative, and partially 
communicative. He had temporo-spatial orientation 
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and only presented a slight attention deficit. He 
denied any hallucinations and alcohol consumption, 
referring only to the chronic consumption of 
psychoactive substances.  
The general medical examination was 
unremarkable. His blood pressure was 136/96 
mmHg, pulse = 90 beats/minute, temperature = 
36.30C, and glycemia = 113 mg/dl. There were no 
relevant family risk factors for neoplastic disease. 
One day after his admission in the psychiatric 
unit, the patient's condition progressively worsened. 
The vomiting was triggered with a continuous 
frequency, even from the sitting position. Brain 
computer tomography (CT) scans, carried out in 
emergency, highlighted a large, irregularly shaped 
fronto-temporo-parietal expansive mass lesion, 
being hypo- and isointense on native examination, 
and with evidence of post-contrast heterogeneous 
enhancement; it was surrounded by an edema and 
induced an important mass effect. He was 
transferred to the 2nd Neurosurgery Clinic, “Prof. dr. 
N. Oblu” Emergency Clinical Hospital, Iasi, Romania, 
and a surgical intervention was performed the same 
day after admission with partial tumour resection. 
The histopathological examination identified an 
astrocytic tumour of low cellularity, moderate 
nuclear atypia and focal microcystic degeneration 
(Figure 1, A and B). Some tumoural cells 
demonstrated apoptotic changes (smaller size, dark 
eosinophilic cytoplasm, condensed and 
hyperchromatic chromatin) (Figure 2, C and D). There 
were only few thin-wall vessels with near normal 
morphology (Figure 2,E and F). The diagnosis of a 
secondary anaplastic astrocytoma, WHO grade III 
(30), developed into a diffuse astrocytoma was 
established. 
Approximately two weeks after his brain tumour 
surgery, the patient once again presented himself to 
our neurosurgical department with nausea, 
vomiting, diffuse headache, vertigo, and an episode 
of convulsive crisis. Blood pressure was 130/70 
mmHg, pulse = 88 beats/minute, and temperature = 
36,8OC. Neurological examination showed left facial 
paresis, muscular weakness and a slightly loss of 
sensibility of his left part of the body. Some minimal 
changes of the preoperative laboratory investigation 
due to previous surgery were identified. There were 
a slightly increased absolute number of WBC 
(13.03x103 /mm3) and slightly elevated 
polymorphonuclear neutrophils (71.3%) on a 
differential count. In addition, a slightly 
fibrinogenemia (465 mg/dl) and slight hyperglycemia 
(120mg/dl) were recorded. 
Brain CT scans revealed a right fronto-temporo-
parietal enhancing tumour with a digitiform 
perilesional edema, with larger dimensions than the 
first tumour and with compression and dislocation of 
medial cerebral structures to the left (approximately 
13.1 mm).  
The patient underwent surgical therapy with 
partial resection of the tumour. The microscopical 
exam of hematoxylin-eosin (H&E) stained 
histological specimens revealed a highly malignant 
glial tumour made up of large, grotesque looking 
multinucleated giant cells, some containing up to 7 
nuclei with abnormal shapes (Figure 4, A-D). Some of 
the nuclei contained prominent nucleoli and atypical 
mitotic figures. There were numerous blood vessels 
of various sizes and shapes, many of them 
presenting marked endothelial proliferation (Figure 
4, E and F). Both large and small areas of ischemic 
necrosis were also observed. Histological 
reevaluation of all the available specimens 
highlighted the fact that the tumour was in fact a 
secondary giant cell glioblastoma (sgcGB), WHO 
grade IV (30), developed in a diffuse astrocytoma 
NOS. 
One week after surgery the patient had a first 
check-up brain IRM scan that revealed an increase in 
the size of the lesion. The patient was referred to the 
Regional Institute of Oncology in order to be treated 
with adjuvant chemotherapy (with temozolomide) 
and radiotherapy. It should be mention that the 
patient didn’t use any psychostimulants in all during 
this period.  
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FIGURE 1. Preoperative axial head computed tomography scan (A. native; B. after contrast administration) performed on patient's 
first admission showed a large irregularly outlined cerebral lesion with central necrosis, peripheral contrast uptake, 
compression and dislocation of medial cerebral structures to the left. 
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FIGURE 2. Histological sections of the first excised sample identified a glial tumor with focal microcystic degeneration and 
moderate cell density, made up of uniform cells resembling mature astrocytes, accompanied by dispersed anaplastic cells [A. 
(H&E, x10); B. (H&E, x40)]; at higher magnification, some tumoral cells revealed apoptotic changes (smaller size, dark 
eosinophilic cytoplasm, condensed and hyperchromatic chromatin) [C. (H&E, x40); D. (H&E, x100)]; there were also thin-wall 
vessels with near normal morphology, but surrounded by anaplastic astrocytic cells [E. (H&E, x100); F. (H&E, x100)]. 
 
 
  
 
FIGURE 3. Axial head computed tomography scans (A. native, B. after contrast administration) performed on patient's second 
admission (at two weeks after first tumor resection) identified temporal scalp swelling, temporal craniotomy and increased 
lesion size with compression and dislocation of medial cerebral structures to the left. 
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FIGURE. 4. Histological section of the second excised sample pointed out a glial tumor with moderate cell density, and cellular 
and nuclear pleomorphism [A. (H&E, x40); B. (H&E, x40); a higher magnification revealed in some other areas a highly cellular 
tumor tissue made up of bizarre looking, giant glial cells, with rich eosinophilic cytoplasm and one or many hyperchromatic 
irregular shaped nuclei [C. (H&E, x100); D. (H&E, x100)]; in areas close to the central part of the tumor there were many thick-
wall vessels with disordered arrangement and moderate endothelial and pericytic proliferation [E. (H&E, x20); F. (H&E, x40)]. 
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FIGURE 5. Axial MR images (A. FLAIR; B. T1 gadolinium-weighted) performed at one week after the second surgery highlighted a 
huge heterogeneous infiltrating mass that filled frontal, temporal and parietal lobes, with extensive peripheral edema and 
midline shift, all these features being indicative of rapid tumor progression. 
 
 
 
DISCUSSION 
The World Health Organization (WHO) defines 
multiple drug use “as the use of more than one drug 
or type of drug by an individual, often at the same 
time or sequentially, and usually with the intention of 
enhancing, potentiating, or counteracting the effects 
of another drug” (31). The most common association 
is with caffeine, nicotine and alcohol. However, the 
most important is the association of cocaine, with 
various combinations of heroin, barbiturates, and 
marijuana.  
Our patient, a multiple drug abuser, who used at 
least four types of drugs (cocaine, heroin, marijuana, 
and nicotine) during a period of at least 10 years, 
presented a glioblastoma that developed in his right 
fronto-temporo-parietal area, which is known to be 
affected by alterations due to drug abuse (32).  
Major neuropathological mechanisms underlying 
chronic abuse of recreational psychostimulants 
(such as cocaine) or nicotine consist of pronounced 
levels of oxidative stress and mitochondrial 
dysfunction in the blood-brain-barrier (BBB) 
endothelium and perivascular cells, i.e. astrocytes, 
due to an uncontrolled increase in cellular reactive 
oxygen and nitrogen species (33, 34). The abuse of 
drugs also induces neuroinflammatory signals and 
disrupts glutamate homeostasis through their 
interaction with microglia and astrocytes (35). 
The German legist Andreas Büttner, who 
extensively investigated the neuropathological 
changes induced by chronic drug abuse, considered 
that the alterations of the intracellular messenger 
pathways, transcription factors and immediate early 
genes within the brain reward system are the most 
important factors for the development of addiction 
(25). 
In 2016, some American researchers concluded 
that cocaine determines the proliferation of human 
astrocytes as this drug increased cyclin A2 (an 
essential regulator of the cell cycle) expression in 
human astrocytes. Lee et al. used cocaine with 
various concentrations and applied them to human 
astrocyte culture. They found that cocaine with 
increasing concentrations significantly increased 
human astrocyte proliferation using the JNK MAP 
kinase pathway as a driver of cell proliferation (36). 
A B 
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In the same year, certain other American researchers 
(37) reported the potential of the psychostimulant 
drugs such as cocaine in inducing astrogliosis 
through the sequential activation of endoplasmic 
reticulum stress and autophagy in human 
astrocytes.  
It was possible to demonstrate that cocaine could 
also induce microglial activation via both the 
endoplasmic reticulum stress and autophagy 
pathways (38, 39). Cocaine potentially modulates the 
immune response in the CNS leading to an 
neuroinflammatory state that is characterized by 
enhanced activation of glial cells in the brains of 
addicts (40) as it seems that cocaine-mediated-
increased upregulation of GFAP correlated with 
increased expression of proinflammatory mediators 
such as TNF, IL1B, and IL6 (37). 
Reactive astrocytosis and microgliosis are 
classical features underlying neuroinflammation 
observed in drug abusers and in various 
neurodegenerative diseases. Astrogliosis is 
accompanied by the release of a wide range of 
neurotoxic mediators consisting of chemokines, 
complementary factors, cytokines, growth factors 
and reactive oxygen species (41), which remodel the 
cellular homeostasis in the CNS. 
Recently, it has been reported that reactive 
astrocytes are prone to develop gliomas. Taken into 
consideration, the older Hansemann concept that 
tumours were derived by dedifferentiation of mature 
cells, it is possible to consider that astrocytes are able 
to dedifferentiate into a pluripotent precursor as a 
critical step in gliomagenesis (42, 43). In 2002, 
Bachoo et al. showed that combined loss of 
p16(INK4a) and p19(ARF), but not of p53, p16(INK4a), 
or p19(ARF), enables astrocyte dedifferentiation in 
response to EGFR activation (44) (https://www.ncb 
i.nlm.nih.gov/pmc/articles/PMC3033226/ - R61) thus 
suggesting a possibility that an astrocyte, due to 
some extrinsic factors in its environment, could 
acquire some mutations necessary for its oncogenic 
transformation.  
Based on all these scientific facts and the 
histopathological features of our patient’s tumour 
that revealed a sgcGB developed in a diffuse 
astrocytoma, we can presume that during those five 
years of cocaine use, astrogliosis and then 
gliomagenesis have been triggered. Firstly, a low 
grade astrocytoma developed as we were able to see 
in the peripheral areas of the tumour. As he began to 
use heroin and marijuana, it is more likely that these 
substances had beneficial effects by reducing 
edemas, intra tumoural inflammation and the 
progression of the disease due to tumour cells 
apoptosis as some other reports have shown (45-46). 
Because our patient wasn’t able to buy cocaine, 
heroin or marijuana over the last three years 
(however only ethnobotanical drugs containing at 
least benzodiazepine) the tumour slowly progressed 
to an anaplastic astrocytoma and ultimately to 
secondary glioblastoma as the histopathological 
features of these two tumours can be seen in the 
middle portion and in the center of the tumour, 
respectively. Also, the absence of the symptoms 
induces by glioblastoma could correlate with the 
inhibitory role of benzodiazepine on glioblastoma 
proliferation (47). However, when the tumour had 
grown to considerable size, the patient presented 
periods of apathy alternating with periods of 
nervousness and ultimately somnolence, nausea 
and vomiting, that led him to the psychiatrist. 
Many scientific studies have indicated the 
potential use of cannabinoids in the fight against 
cancer. Experiments carried out on cell lines in vitro 
and on animal models in vivo have shown that 
phytocannabinoids, endocannabinoids, synthetic 
cannabinoids and their analogues can lead to 
inhibition of the growth of many tumour types, 
exerting cytostatic and cytotoxic neoplastic effects 
on cells thereby negatively influencing neo-
angiogenesis (48). Our patient's glioblastoma 
showed extensive necrotic areas, however intra 
tumoural microvasculature was reduced and there 
was only mild proliferation of the pericytes, 
demonstrating neoangiogenesis inhibition probably 
due to the toxic effect of multiple drugs abuse.  
Pokrywka et al. have shown that the main 
molecular mechanism leading to inhibition of glioma 
cell by cannabinoids is apoptosis, being a 
consequence of induction of endoplasmic reticulum 
stress and autophagy (49). Indeed, a detailed 
examination of our patient's histological samples 
revealed many apoptotic tumour cells with cell 
shrinkage, dark eosinophilic cytoplasm, and 
condensed chromatin.  
Forty years ago, White et al. (50) demonstrated 
the fact that cannabinoids inhibited tumour growth 
because delta9-tetrahydrocannabinol (delta9-THC) 
decreased DNA synthesis in transformed cell 
cultures. More recently, other studies have 
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investigated the molecular mechanism of anti-
cancer effect of cannabinoids and have found that 
these substances inhibited tumour cell growth and 
induced apoptosis by modulating different cell 
signaling pathways e.g. via the upregulation of the 
endoplasmic reticulum stress-related genes ATF-4, 
CHOP, and TRB3 (51). Delta (9)-tetrahydrocannabinol 
(THC), the main active component of marijuana, 
induces human glioma cell death through 
stimulation of autophagy, a precursor event of 
apoptosis (52, 53). 
The first clinical study with the aim to evaluate 
cannabinoid anti tumoural action was a pilot study 
conducted in 2006 in a cohort of terminal patients 
harbouring recurrent glioblastomas (54). All these 
patients were administered Δ9-
Tetrahydrocannabinol intra tumouraly. Inhibition of 
tumour-cell proliferation in vitro and decreased 
tumour-cell Ki67 immunostaining were observed.  
Literature has shown that giant cell glioblastoma 
represented a distinct pattern of cytogenetic 
alterations when compared with small cell 
glioblastoma and suggested that multinuclear giant 
cells evolved from a non-giant tumour cell at an early 
tumour stage (51). Routine histological preparations 
of our patient's surgical specimens showed a variety 
of characteristic changes in tumour cell and nuclear 
morphology (prominent formation of giant 
monstrous cells, with bizarre, irregular, and 
hyperchromatic nuclei, a decrease in the number of 
mitoses, and severe cytoplasmic degeneration) 
indicating inhibition of tumour cell division. These 
morphological changes, quite similar with those 
induced by chemotherapy on glioma cells (56, 57), 
probably represent the effects of drug abuse on glial 
tumour cells.  
Johnson and Weissman also reported an 
interference of cocaine with cell replication as it 
produced fine structural nuclear alterations in 
cultured neuroglioblastoma cells. (58). In 1993, Garg 
et al. exposed C6 glioma cells to cocaine and 
observed a reduced thymidine and uridine 
incorporation in these cells after four days of 
exposure (59). After almost ten years, other 
experimental studies have shown that various 
concentrations of cocaine caused a significant down-
regulation of CYP2C8 and CYP2C9 genes and a 
decrease in the level of cellular protein in human 
U373 MG astrocytoma cells (60). More recently, 
Badisa et al. have demonstrated that the dual 
inhibition of cell cycle phases at G0/G1 and G2/M 
could appear in C6 glioma cells exposed to cocaine 
(61). 
All these articles represent the evidence that 
cocaine exposure may be the cause for the 
appearance of monstrous, bizarre looking nuclei 
identified in our patient's tumoural astrocytes as 
their cell cycle was affected. The main molecular 
mechanism leading to inhibition of proliferation of 
cancer cells by cannabinoids is apoptosis (49) which 
was also identified in great number in our patient's 
histological sections.  
 
CONCLUSION 
The effects of illicit psychostimulant drugs exposure 
are not fully known. The morphological features 
identified in the histological samples of our patient 
revealed a sgcGB developed in a diffuse astrocytoma 
and in this respect, the case we presented in this 
paper was able to confirm the gliomagenesis effect 
of chronic multiple drug abuse. On the other hand, 
the drugs could have had inhibitory effects on 
tumour cells growth because, although the tumour 
was large in size and caused brain sub-falcine 
herniation, the patient only reported the onset of 
seizures late in the evolution.  
 Alongside the toxic effects on healthy organs and 
systems, these illicit drugs also have the effects of 
both inducing and inhibiting cancerogenesis, 
depending on the type of the drug. Therefore, the 
diagnosis of a brain tumour should take into 
consideration not only patient's clinical and imaging 
data, but also his lifestyle, especially his addiction to 
recreational drugs. 
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